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ABSTRACT
Background Osteoclasts play a critical role in bone resorption under basal conditions, but they also contribute
to pathological bone loss during diseases including postmenopausal osteoporosis. Phospholipase Cc2 (PLCc2) is
an important signalling molecule in diverse haematopoietic lineages. Here, we tested the role of PLCc2 in basal
and ovariectomy-induced bone resorption, as well as in in vitro osteoclast cultures using PLCc2-deﬁcient
(PLCc2
) ⁄ )) mice.
Materials and methods The trabecular architecture of long bone metaphyses was tested by micro-CT and
histomorphometric analyses. Postmenopausal osteoporosis was modelled by surgical ovariectomy. Osteoclast
development and function, gene expression and PLCc2 phosphorylation were tested on in vitro osteoclast and
macrophage cultures.
Results PLCc2
) ⁄ ) mice had signiﬁcantly higher trabecular bone mass under basal conditions than wild-type
mice. PLCc2 was required for in vitro development and resorptive function of osteoclasts, but not for upregula-
tion of osteoclast-speciﬁc gene expression. PLCc2 was phosphorylated in a Src-family-dependent manner upon
macrophage adhesion but not upon stimulation by M-CSF or RANKL. Surprisingly, ovariectomy-induced bone
resorption in PLCc2
) ⁄ ) mice was similar to, or even more robust than, that in wild-type animals.
Conclusions Our results indicate that PLCc2 participates in bone resorption under basal conditions, likely
because of its role in adhesion receptor signalling during osteoclast development. In contrast, PLCc2 does not
appear to play a major role in ovariectomy-induced bone loss. These results suggest that basal and oestrogen
deﬁciency–induced bone resorption utilizes different signalling pathways and that PLCc2 may not be a suitable
therapeutic target in postmenopausal osteoporosis.
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Introduction
While osteoclasts are important for normal bone turnover, they
also contribute to pathological bone loss during osteoporosis,
rheumatoid arthritis or osteolytic bone metastases [1–3]. How-
ever, it is incompletely understood how osteoclasts contribute
to normal and pathological bone resorption and whether they
utilize similar intracellular signalling machineries during the
two processes.
Osteoclasts are highly specialized phagocytic cells of haemat-
opoietic origin [4]. They develop by an initial macrophage-like
differentiation, followed by reprogramming to the osteoclast
lineage and fusion of preosteoclasts to mature multinucleated
osteoclasts [1,4]. These processes are directed by the M-CSF and
the osteoblast-derived RANK ligand (RANKL) cytokines.
A number of recent studies have indicated similar compo-
nents of osteoclast biology and immune mechanisms, leading
to the emergence of the new ﬁeld of osteoimmunology [5].
Those similarities include activation by closely related cyto-
kines [5–7], shared use of transcription factors [5,8,9] and the
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ORIGINAL ARTICLErole of immunoreceptor-like signalling pathways (such as Syk
activation by immunoreceptor-associated adapters) in
osteoclast development [10–14]. The similarity between bone
and immune cells is further supported by the similar compo-
nents used by neutrophil, macrophage and osteoclast signalling
and in vivo inﬂammatory processes [15–19].
Phospholipase Cc (PLCc) proteins link tyrosine kinase-cou-
pled receptors to Ca
2+ signalling and PKC activation [20]. While
the PLCc1 isoform is ubiquitously expressed and is required
for embryonic development [21,22], PLCc2 is primarily present
in haematopoietic lineage cells and its absence triggers defects
in haematopoietic lineage cells [23–28]. Most of those pheno-
types are also shared with Syk
) ⁄ ) mice or mice with genetic
defects of immunoreceptor signalling molecules [15,19,29,30].
PLCc2 is also activated downstream of the immunoreceptor
signalling adapters DAP12 and the Fc-receptor c-chain (FcRc)
in osteoclast precursors while the downstream activation of the
NFATc1 transcription factor is mediated by Ca
2+ signalling
through tyrosine phosphorylation pathways [11,31]. The over-
all similarity between immunoreceptor and PLCc2-mediated
signalling pathways suggests a possible role for PLCc2i n
osteoclast biology.
The above results prompted us to test the role of PLCc2i n
osteoclast development and function, as well as in in vivo bone
homeostasis under normal and pathological conditions. Our
results indicate that PLCc2 plays an important role in basal
bone resorption, likely due to its role in later phases of
osteoclast development. Surprisingly, however, PLCc2 does
not play a major role in ovariectomy-induced bone loss.
Materials and methods
Animals
Heterozygous mice carrying a deleted allele of the PLCc2-
encoding gene (Plcg2
tm1Jni, referred to as PLCc2
)) [23] were
obtained from James N. Ihle (St. Jude Children’s Research
Hospital, Memphis, TN, USA) and has been backcrossed to the
C57BL⁄6 genetic background for more than 10 generations.
Because of the limited fertility of homozygous PLCc2
) ⁄ ) mice,
the mutation was maintained in heterozygous form as
described [26].
For in vivo experiments, PLCc2
+ ⁄ + or PLCc2
+ ⁄ ) mice of
identical age and sex (mostly littermates) from the same colony
were used as controls. For in vitro experiments, either PLCc2-
sufﬁcient mice from the PLCc2 breeding colony or C57BL⁄6
mice purchased from the Hungarian National Institute of
Oncology (Budapest, Hungary) were used as controls. Because
of the limited availability of PLCc2
) ⁄ ) animals, some of the in
vitro experiments were performed on cells from PLCc2
) ⁄ ) (and
appropriate control) bone marrow chimeras generated and
tested as described [26]. No difference between the different
sources of mice or bone marrow cells has been observed (not
shown).
Mice were kept in individually sterile ventilated cages (Tec-
niplast, Buguggiate, Italy) in a conventional facility. All animal
experiments were approved by the Semmelweis University
Animal Experimentation Review Board.
Ovariectomy
To test oestrogen deﬁciency–induced bone loss, wild-type
and PLCc2
) ⁄ ) females at 8 weeks of age were anesthetized
with ketamine and medetomidine and subjected to surgical
ovariectomy or sham operation. Six weeks after the operation,
the mice were sacriﬁced and their femurs or tibias were
analysed.
Micro-CT and histomorphometry
Bone architecture under basal conditions was tested on age-
matched wild-type and PLCc2
) ⁄ ) male mice at 8–10 weeks of
age. Ovariectomy-induced bone loss was tested at 14 weeks of
age on wild-type and PLCc2
) ⁄ ) females.
Micro-CT studies were performed on the distal metaphysis
of the femurs stored in PBS containing 0Æ1% Na-azide. Samples
were scanned on a SkyScan 1172 (SkyScan, Kontich, Belgium)
micro-CT apparatus using a 50 kV and 200 lA X-ray source
with 0Æ5-mm aluminium ﬁlter, and a rotation step of 0Æ5  with
frame averaging turned on, resulting in an isometric voxel size
of 4Æ5 lm. Three-dimensional images were reconstituted and
analysed using the NRecon and CT-Analyser software (both
from SkyScan). For quantitative analysis, 400 horizontal sec-
tions starting 50 sections above the distal growth plate were
selected, and the boundaries of trabecular area were selected
manually a few voxels away from the endocortical surface [32].
The density threshold for bone tissue was set manually by an
experienced investigator. For graphical presentation, the two-
dimensional representation of a horizontal section 250 sections
above the distal growth plate, as well as the three-dimensional
reconstitution of an axial cylinder of 700 lm diameter, expand-
ing from 150 to 450 sections above the distal growth plate has
been prepared.
Histomorphometry studies were performed on the proximal
metaphysis of the tibias. After sacriﬁcing the mice, the bones
were placed in 70% ethanol, then ﬁxed overnight in 4%
formalin and embedded undecalciﬁed in methylmetacrylate
(Technovit; Heraeus Kulzer, Wehrheim, Germany). After
polymerization, 3- to 4-lm sections were cut with a Jung
micrometer (Jung, Heidelberg, Germany) and deplastinated in
methoxymethylmetacrylate (Merck, Darmstadt, Germany).
Sections were stained with von Kossa and Goldner stains. Bone
histomorphometry was performed using a microscope (Nikon,
Tokyo, Japan) equipped with a video camera and digital analy-
sis system (OsteoMeasure; OsteoMetrics, Decatur, GA, USA).
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international standards [33] as described [34].
In vitro cultures, resorption assays and ﬂow
cytometry
Suspensions of bone marrow cells were cultured for 48 h in
a-MEM (Invitrogen, Carlsbad, CA, USA) in the presence of
10 ng⁄mL recombinant mouse M-CSF (Peprotech, Rocky Hill,
NJ, USA). Nonadherent cells (osteoclast⁄macrophage precur-
sors) were then plated at 0Æ5 million per cm
2 and cultured in
the presence of 20 or 50 ng⁄mL mouse M-CSF or mouse
RANKL (Peprotech) with media changes and replacement of
the cytokines every 2–3 days. Cellular morphology and tar-
trate-resistant acid phosphatase (TRAP) expression were
determined after 3–5 days of culture in 24-well tissue culture-
treated plates using a commercial TRAP staining kit (Sigma,
St. Louis, MO, USA). For in vitro resorption assays, osteoclast
precursors were plated on BD BioCoat Osteologic slides (BD
Biosciences, Bedford, MA, USA), cultured in the presence of
M-CSF and RANKL for 10–14 days and processed according
to the manufacturer’s instructions. Cultures were observed
and imaged using a Leica Microsystems (Wetzlar, Germany)
DMI6000B inverted microscope. The number of osteoclasts
(i.e. TRAP-positive cells with 3 or more nuclei) was counted
manually, while the percentage of resorbed area was deter-
mined using the IMAGEJ software (NIH, Bethesda, MD, USA).
Macrophages were generated by culturing osteoclast⁄
macrophage precursors in the presence of M-CSF but not
RANKL. M-CSF was supplied in the form of puriﬁed protein
(parallel macrophage and osteoclast studies) or as a 10%
conditioned medium from CMG14-12 cells [35] (biochemical
studies). Expression of the F4⁄80 macrophage differentiation
antigen was tested as described [19].
Analysis of gene expression
Osteoclast-speciﬁc gene expression was tested using quantita-
tive real-time PCR analysis [36] from wild-type or PLCc2
) ⁄ )
cultures generated in the indicated periods of time using the
indicated cytokine concentrations. Total RNA was then iso-
lated from the cells with Trizol reagent (Invitrogen). Reverse
transcription was performed at 37  C for 120 min from 100 ng
total RNA using the High Capacity cDNA Archive Kit
(Applied Biosystems, Foster City, CA, USA). Quantitative real-
time PCRs were performed in triplicates with a control reaction
containing no reverse transcriptase on an ABI PRISM 7900
(Applied Biosystems) equipment with 40 cycles at 94  C for
12 s and 60  C for 60 s using Applied Biosystems Taqman
Gene Expression Assay kits. We tested the expression of the
mouse Acp5 (TRAP; Taqman Mm00475698_m1), Calcr
(Calcitonin receptor; Mm00432271_m1), Ctsk (cathepsin K;
Mm00484039_m1), Fos (c-Fos; Mm00487425_m1), Nfatc1
(NFATc1; Mm00479445_m1), Oscar (OSCAR; Mm00558665_
m1) and Tm7sf4 (DC-STAMP; Mm04209235_m1) genes and
normalized it to the expression of the housekeeping gene
Gapdh (GAPDH; Mm99999915_g1). The comparative Ct method
was used to quantify transcripts.
Biochemical and signalling studies
PLCc2 expression was determined from Triton X-100-soluble
whole osteoclast or macrophage lysates as described [26].
For signalling studies, macrophages were cultured for
5–8 days in bacterial dishes, suspended with 5 mM EDTA and
serum starved for 6 h. When indicated, the cells were then
incubated with 10 lM PP2 (EMD Biosciences, Darmstadt,
Germany) for 8 min. The cells were stimulated with 50 ng⁄mL
M-CSF or 50 ng⁄mL RANKL in suspension or were plated on
6-cm tissue culture-treated dishes. The reaction was stopped
after 30 min at 37  C, and cell lysates were prepared as
described [26]. PLCc2 was precipitated using the Q-20 PLCc2
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and captured using a 1 : 1 mixture of Protein A Sepharose
(Zymed, South San Francisco, CA, USA) and Protein G Aga-
rose (Invitrogen). Whole-cell lysates or PLCc2 immunoprecipi-
tates were immunoblotted with phosphorylation-speciﬁc
antibodies (from Cell Signaling Technology, Danvers, MA)
against PLCc2 (pTyr 759; #3874), ERK (#9101) or the p38 MAP
kinase (#9211); nonphospho-speciﬁc antibodies against PLCc2
(Q-20; Santa Cruz), ERK1⁄2 (combination of C-16 (ERK1) and
C-14 (ERK2) from Santa Cruz), p38 MAP kinase (C-20; Santa
Cruz), IjBa (#9242; Cell Signaling) or b-actin (AC-74; Sigma);
or antibodies against phosphotyrosine (clone 4G10; Millipore,
Billerica, MA, USA). Signal intensity was developed using sec-
ondary antibodies and ECL reagents from GE Healthcare
(Chalfont St. Giles, UK).
Statistical analysis
Experiments were performed at the indicated times with
comparable results. Statistical analyses were performed using
Student’s unpaired two-population t-test with unequal
variance or by two-way ANOVA. Analysis of the interaction
between the effects of genotypes and surgical treatments was
performed using Tukey’s post hoc test. P values below 0Æ05
were considered statistically signiﬁcant.
Results
micro-CT and histomorphometric analysis of
wild-type and PLCc2
)⁄) animals
We ﬁrst analysed the composition of trabecular bone of wild-
type and PLCc2
) ⁄ ) male mice using micro-CT analysis of the
distal metaphysis of the femurs. Signiﬁcantly more trabeculae
were visible in PLCc2
) ⁄ ) animals than in the wild-type mice
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PLCc2 IN BONE METABOLISMboth in raw micro-CT slices (Fig. 1a) and in three-dimensional
reconstitution images of an axial cylindrical region (Fig. 1b).
Quantiﬁcation of the entire three-dimensional reconstitution
image (Fig. 1c) revealed a signiﬁcant increase in the per cent
bone volume (BV⁄TV) of PLCc2
) ⁄ ) animals (P =0 Æ011; n = 5),
which was primarily because of increased trabecular number
rather than increased thickness of the individual trabeculae
(Fig. 1c).
We also performed histomorphometric analysis of the trabec-
ular bone of the proximal tibia of male mice. Those studies con-
ﬁrmed an increased relative bone volume (BV⁄TV; P =0 Æ0012;
n = 4) and trabecular number, but not trabecular thickness is
PLCc2
) ⁄ ) animals (Fig. 1d). In addition, a signiﬁcantly lower
number of osteoclasts was seen in PLCc2
) ⁄ ) bones while the
number of osteoblasts was not affected (Fig. 1e). Taken
together, PLCc2
) ⁄ ) animals have increased trabecular bone
volume likely due to an osteoclast defect.
PLCc2 is required for in vitro osteoclast development
Totest therole of PLCc2in osteoclasts, we havecultured wild-
typeandPLCc2
) ⁄ ) bonemarrow cells under osteoclastogenic
conditions in vitro.As shown in theTRAP-stained images in
Fig. 2a andtheir quantiﬁcation in Fig. 2b, 20 ng⁄mL M-CSF and
20 ng⁄mL RANKL inducedsigniﬁcant osteoclast development
from wild-type butnot fromPLCc2
) ⁄ ) bonemarrow cells.This
defect could notbe overcome byincreasing theconcentration of
M-CSF,RANKL or both to50 ng⁄mL(Figs 2a,b).However, both
wild-type andPLCc2
) ⁄ ) culturesconsistently stained positive
for TRAP(Fig. 2c), andthe percentageof TRAP-positive cells
among all mononuclear cells was verysimilar in thetwo
(a) (b)
(e) (c)
(d)
Figure 1 Micro-CT and histomorphometric analysis of intact PLCc2
) ⁄ ) mice. (a–b) Representative micro-CT sections (a) and three-
dimensional reconstitution (b) of the trabecular area of the distal femoral metaphysis of age-matched wild-type (WT) and PLCc2
) ⁄ )
male mice. Distal regions are shown to the lower right in panel b. (c,d) Quantitative micro-CT (c) and histomorphometric (d) analysis
of the trabecular bone architecture. (e) Histomorphometric analysis of the number of osteoclasts (OC) or osteoblasts (OB) attached
to the trabecular bone surface. Data were obtained from ﬁve (a–c) or four (d,e) mice per group at 8–10 weeks of age. The analyses
were performed on the distal metaphysis of the femurs (a–c) or the proximal metaphysis of the tibias (d,e). Error bars represent
SEM. *P <0 Æ05; **P <0 Æ01; ***P <0 Æ002; n.s., not signiﬁcant; BV⁄TV, per cent bone volume (bone volume⁄total volume).
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and40–45%at 50 ng⁄mL M-CSF and50 ng⁄mL RANKL, irre-
spective of the genotype of the cells). Takentogether, PLCc2is
required for thein vitrodevelopment of mature multinucleated
osteoclasts in the presence of M-CSF andRANKL butlikely not
for theinitial steps of preosteoclast differentiation.
PLCc2 is required for in vitro bone resorption
We next tested the effect of PLCc2 deﬁciency on osteoclast-
mediated bone resorption by culturing bone marrow cells on an
artiﬁcial hydroxyapatite layer. As shown in Fig. 3, wild-type
cells cultured in the presence of 20 ng⁄mL M-CSF and
20 ng⁄mL RANKL had a moderate resorptive capacity that was
strongly increased by increasing the concentration of both cyto-
kines to 50 ng⁄mL. In contrast, practically, no resorption could
be observed in PLCc2
) ⁄ ) cultures at either cytokine
concentration. Therefore, PLCc2 is also required for osteoclast-
mediated bone resorption, likely reﬂecting the previously
mentioned osteoclast developmental defect (Fig. 2).
PLCc2 is not required for macrophage differentiation
or expression of osteoclast-speciﬁc genes
Our next aim was to address whether PLCc2 is involved in an
earlier or a later phase of osteoclast differentiation. Because we
were able to obtain normal numbers of apparently normal
macrophages from PLCc2
) ⁄ ) bone marrow cells (Fig. 2c and
data not shown) and those macrophages expressed normal
levels of the macrophage differentiation marker F4⁄80 (Fig. 4a),
it is unlikely that PLCc2 is required for the ﬁrst steps of general
myeloid cell differentiation.
We next tested the time course of osteoclast-speciﬁc gene
expression in in vitro cultures by quantitative RT-PCR. As
(a)
(b) (c)
Figure 2 PLCc2 is required for in vitro osteoclast development. (a) Representative TRAP-stained images of wild-type (WT) and
PLCc2
) ⁄ ) bone marrow cells cultured in the presence of the indicated concentrations of recombinant murine M-CSF and RANKL for
4 days. (b) Number of multinucleated osteoclasts (TRAP-positive cells with 3 or more nuclei) in cultures of WT and PLCc2
) ⁄ ) bone
marrow cells treated with the indicated concentrations of M-CSF and RANKL for 4 days. (c) Enlarged view of TRAP-stained
osteoclast and macrophage cultures generated in the presence of 20 ng⁄mL M-CSF with (osteoclasts) or without (macrophages)
20 ng⁄mL RANKL for 4 days. Results were obtained from 15 (a,b) or 7 (c) independent experiments per group. Error bars represent
SEM. n. d., not detected.
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TRAP), Calcr (calcitonin receptor), Ctsk (cathepsin K), Fos
(c-Fos), Nfatc1 (NFATc1), Oscar (OSCAR) and Tm7sf4 (DC-
STAMP) genes was strongly increased during osteoclast differ-
entiation, but none of these genes showed increased expression
in parallel macrophage samples. The genetic deﬁciency of
PLCc2 did not induce any major reduction in osteoclast-spe-
ciﬁc gene expression, although some partial decrease in
expression could be observed, particularly in the case of Calcr
(Fig. 4b). Most importantly, the expressions of the genes
encoding for the early maturation marker TRAP (Acp5), the
most plausible PLCc2 effector NFATc1 (Nfatc1) [11,31] and of
DC-STAMP (Tm7sf4), a critical player of the preosteoclast
fusion machinery [37,38], were all upregulated normally in
PLCc2
) ⁄ ) cultures (Fig. 4b). These results indicate that PLCc2
is mostly dispensable for initiation of osteoclast-speciﬁc gene
expression.
Biochemical characterization of the PLCc2-mediated
osteoclast signalling pathway
Next, we aimed at the biochemical characterization of PLCc2
activation in osteoclasts. We ﬁrst tested the presence of PLCc2
in parallel macrophage and osteoclast cultures and found that
PLCc2 was expressed at comparable levels in wild-type macro-
phages and osteoclasts but, as expected, not in PLCc2
) ⁄ ) cells
(Fig. 5a).
Osteoclast development is triggered by three major extracel-
lular signals: M-CSF, RANKL and adhesive interactions with
the environment (e.g. with tissue culture plastic surface).
We next tested which of these three signals trigger PLCc2 acti-
vation, using wild-type macrophages stimulated with M-CSF
or RANKL in suspension (which was required to avoid parallel
engagement of adhesion receptors), or plated on a tissue culture
plastic surface. Both an immunoprecipitation approach
followed by immunoblotting with anti-phosphotyrosine
antibodies (Fig. 5b) and a direct immunoblotting using
phospho-speciﬁc PLCc2 antibodies (Fig. 5c) revealed PLCc2
phosphorylation upon adhesion of macrophages but not upon
M-CSF or RANKL stimulation in suspension. Additional
attempts with M-CSF or RANKL stimulation for various peri-
ods of time or using various cytokine concentrations ranging
from 10 to 100 ng⁄mL did not reveal a consistent PLCc2 phos-
phorylation in suspension either (not shown). On the other
hand, M-CSF-induced ERK phosphorylation and RANKL-
induced p38 MAP kinase phosphorylation and NFjB activation
(degradation of IjBa) could readily be observed under these
conditions (Fig. 5c), indicating intact basic M-CSF and RANKL
signalling in suspension. Therefore, PLCc2 appears to be acti-
vated by adhesive interactions rather than by stimulation with
M-CSF or RANKL cytokines.
We have also tested the role of Src-family kinases in PLCc2
phosphorylation. As shown in Fig. 5d, pretreatment of macro-
phages with the Src-family inhibitor PP2 completely abrogated
the PLCc2 phosphorylation response, indicating that the
adhesion-induced PLCc2 activation requires members of the
Src kinase family.
PLCc2
)⁄) mice show normal ovariectomy-induced
bone resorption
Because osteoclast-mediated bone resorption contributes to
postmenopausal osteoporosis [39], we hypothesized that PLCc2
(a)
(b)
Figure 3 PLCc2 is required for in vitro resorptive activity of
osteoclasts. (a) Representative images of resorption of an
artiﬁcial hydroxyapatite layer in wild-type (WT) and PLCc2
) ⁄ )
osteoclast cultures. Bone marrow cells were cultured on BD
BioCoat Osteologic Plates in the presence of the indicated con-
centrations of M-CSF and RANKL for 14 days. (b) Quantiﬁcation
of the in vitro resorptive activity of WT and PLCc2
) ⁄ ) osteoclast
cultures treated with the indicated concentrations of cytokines.
Results were obtained from 3 to 7 independent experiments
per group. Error bars represent SEM. n.d., not detected.
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That possibility was tested by subjecting wild-type and
PLCc2
) ⁄ ) animals to surgical ovariectomy, followed by
micro-CT and histomorphometric analysis 6 weeks later. Rep-
resentative raw micro-CT sections (Fig. 6a), three-dimensional
reconstitution images (Fig. 6b) and quantitative micro-CT
(b) (a)
Figure 4 Normal macrophage development and osteoclast-speciﬁc gene expression. (a) Flow cytometric analysis of the expres-
sion of the F4⁄80 macrophage differentiation marker on wild-type (WT) and PLCc2
) ⁄ ) macrophages generated by culturing bone
marrow cells in the presence of recombinant murine M-CSF. Curves of isotype control-stained cells show non-speciﬁc labelling.
(b) Analysis of the expression of osteoclast-speciﬁc genes in WT and PLCc2
) ⁄ ) osteoclast (OC) and macrophage (MU) cultures. WT
and PLCc2
) ⁄ ) bone marrow cells were cultured in the presence of 50 ng⁄mL with (OC) or without (MU)5 0n g⁄mL RANKL for the
indicated period of time, and then the expression of the Acp5 (TRAP), Calcr (Calcitonin receptor), Ctsk (Cathepsin K), Fos (c-Fos),
Nfatc1 (NFATc1), Oscar (OSCAR) and Tm7sf4 (DC-STAMP) genes was determined using quantitative RT-PCR. The results shown
were obtained from 3 to 6 independent experiments per group. Error bars represent SEM.
(a) (b) (c)
(d)
Figure 5 Cellular adhesion triggers PLCc2 phosphorylation. (a) Expression of PLCc2 in macrophages (MU) and osteoclasts (OC).
Wild-type (WT) and PLCc2
) ⁄ ) bone marrow cells were cultured in the presence of 50 ng⁄mL M-CSF with (OC) or without (MU)
50 ng⁄mL RANKL for 4 days, followed by preparation of whole-cell lysates (WCL) and immunoblotting for PLCc2 and b-actin. B-C,
Stimulus-induced phosphorylation of PLCc2. Wild-type macrophages were treated with 50 ng⁄mL M-CSF, 50 ng⁄mL RANKL or kept
unstimulated in suspension, or they were plated on tissue culture-treated plastic dishes (Adh). After 30 min of incubation, cell was
lysed and processed for immunoprecipitation (IP) of PLCc2 followed by immunoblotting using anti-phosphotyrosine (PY) antibod-
ies, (b) or WCL were immunoblotted using phosphorylation-speciﬁc antibodies against ERK, the p38 MAP kinase (p38) and PLCc2o r
nonphospho-speciﬁc antibodies against IjBa (c). Immunoblotting for ERK, p38 and PLCc2 served as loading control. (d) Role of
Src-family kinases in PLCc2 phosphorylation. Wild-type macrophages were pretreated in the presence or absence of 10 lM PP2 and
then stimulated and their PLCc2 phosphorylation tested as in panel b. Results shown represent 3–5 independent experiments with
similar results.
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PLCc2 IN BONE METABOLISManalyses (Fig. 6c) indicated that, similar to intact male animals
(Fig. 1), sham-operated PLCc2
) ⁄ ) females also had increased
trabecular bone density, which was reﬂected in a nearly two-
fold increase in relative bone volume (BV⁄TV; P =0 Æ00031;
n = 7 (wild type) vs. 4 (PLCc2
) ⁄ ))). As expected, surgical ovari-
ectomy led to a signiﬁcant reduction in the per cent bone
volume (BV⁄TV) of wild-type mice (P =0 Æ025; n = 7). Contrary
to our expectations, however, the per cent bone volume of
PLCc2
) ⁄ ) animals was also signiﬁcantly reduced (P =0 Æ00023;
n = 4) and that reduction was even higher in PLCc2
) ⁄ ) mice
than in wild-type animals both in terms of absolute reduction
in BV⁄TV values (4Æ1 vs. 1Æ6 percentage points, respectively)
and in percentage of the BV⁄TV values of the sham-operated
control animals (50% vs. 36%, respectively). The difference of
the effect of ovariectomy on wild-type and PLCc2
) ⁄ ) animals
(interaction of the genotypes and surgical procedures) proved
to be statistically signiﬁcant (P =0 Æ0090). Importantly, while the
BV⁄TV values of sham-operated wild-type and PLCc2
) ⁄ )
animals were statistically highly signiﬁcant (P =0 Æ00025), there
was no signiﬁcant difference between the two genotypes after
the ovariectomy procedure (P =0 Æ25; n = 7 (wild type) vs. 4
(PLCc2
) ⁄ ))). Similar differences could be observed in the tra-
becular numbers, whereas the trabecular thickness remained
unaffected by the different genotypes and surgical procedures
(Fig. 6c).
The above-mentioned ﬁndings were also conﬁrmed by
histomorphometric analysis of ovariectomy-induced bone loss
in the proximal tibia. As shown in Fig. 6d, that analysis
conﬁrmed the increased per cent bone volume (BV⁄TV) in
sham-operated PLCc2
) ⁄ ) animals (P =0 Æ0010; n = 3) and a
reduction in per cent bone volume in ovariectomized wild-type
mice (P =0 Æ038; n = 3). Importantly, the ovariectomy procedure
induced a signiﬁcantly more pronounced reduction in per cent
bone volume in PLCc2
) ⁄ ) mice than in wild-type animals, both
(a) (c)
(d)
(e)
(b)
Figure 6 PLCc2 is not required for ovariectomy-induced bone resorption. (a,b) Representative micro-CT sections (a) and three-
dimensional reconstitution (b) of the trabecular area of the distal metaphysis of the femur of wild-type (WT) and PLCc2
) ⁄ ) female
mice subjected to surgical ovariectomy (OVX) or a sham operation. Distal regions are shown to the lower right in panel b. (c,d)
Quantitative micro-CT (c) or histomorphometric (d) analysis of the trabecular bone architecture of ovariectomized or sham-operated
mice of the indicated genotypes. (e) Histomorphometric analysis of the number of osteoclasts (OC) or osteoblasts (OB) attached to
the trabecular bone surface. Data were obtained from 7 (WT) or 4 (PLCc2
) ⁄ )) mice per group (a–c) or from three mice per group
(d,e). Surgical operation was performed at 8 weeks of age followed by an additional 6 weeks before the mice were sacriﬁced and
their bones were removed for analysis. Error bars represent SEM of the indicated number of animals. *P <0 Æ05; **P <0 Æ01;
***P <0 Æ002; ****P <0 Æ0004; n.s., not signiﬁcant; BV⁄TV, per cent bone volume (bone volume⁄total volume).
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percentage points, respectively) and in per cent of the BV⁄TV
values of the sham-operated control animals (38% vs. 24%,
respectively). The difference of the effect of ovariectomy on
wild-type and PLCc2
) ⁄ ) animals (interaction of the genotypes
and surgical procedures) proved again to be statistically
signiﬁcant (P =0 Æ013). Similar to the micro-CT data (Fig. 6a),
while the BV⁄TV values of sham-operated wild-type and
PLCc2
) ⁄ ) animals were statistically highly signiﬁcant
(P =0 Æ0010), that difference faded away after the ovariectomy
procedure (P =0 Æ24; n = 3). A similar picture was seen during
the analysis of trabecular numbers, whereas the trabecular
thickness remained unaffected by the different genotypes and
surgical procedures (Fig. 6d).
Additional studies testing the number of osteoclasts and
osteoblasts attached to the bone surface indicated that although
the number of osteoclasts was signiﬁcantly lower in the sham-
operated PLCc2
) ⁄ ) mice than in the wild-type ones (3Æ0±0 Æ1
vs. 1Æ4±0 Æ5 per mm, respectively; P =0 Æ0036; n = 3), the num-
ber of osteoclasts was strongly increased and reached a compa-
rable, though, still signiﬁcantly different level (6Æ3±0 Æ4 vs.
5Æ0±0 Æ4 per mm, respectively; P =0 Æ010; n = 3) in the two
genotypes after the ovariectomy procedure (Fig. 6e). The differ-
ence of the effect of ovariectomy on wild-type and PLCc2
) ⁄ )
animals (interaction of the genotypes and surgical procedures)
did not prove to be statistically signiﬁcant (P =0 Æ56; n = 3),
indicating that PLCc2
) ⁄ ) animals were able to upregulate
osteoclast numbers upon oestrogen deﬁciency normally.
Analysis of the number of osteoblasts did not ﬁnd any signiﬁ-
cant difference between any of the groups tested (Fig. 6e).
Taken together, these results suggest that ovariectomized
PLCc2
) ⁄ ) animals are capable of reducing their bone mass to
levels comparable to those seen in similarly treated wild-type
animals, likely because of similar oestrogen deﬁciency–induced
increase in osteoclast numbers in the two genotypes.
Discussion
In the ﬁrst part of this study, we showed that PLCc2
) ⁄ ) mice
have increased basal bone density, likely due to reduced in vivo
osteoclast number reﬂecting the role of PLCc2 in a later phase of
osteoclast development. These results raised the possibility that
PLCc2 may also participate in pathological bone resorption,
such as oestrogen deﬁciency–induced osteoporosis. Much to
our surprise, however, PLCc2
) ⁄ ) mice showed similar, or even
more pronounced, ovariectomy-induced bone resorption than
their wild-type counterparts. Therefore, PLCc2 does not appear
to be required for oestrogen deﬁciency–induced bone loss.
The experiments presented in this paper (part of which were
published in an abstract form before [40]) were initiated based
on our prior experiments showing defective osteoclast develop-
ment and in vivo bone resorption in mice lacking immunorecep-
tor signalling adapter molecules or the Syk tyrosine kinase [10],
as well as the similarity between various Syk
) ⁄ ) and PLCc2
) ⁄ )
phenotypes [15,19,23–26,41]. However, two other groups have
also independently reported in vitro osteoclast development
and in vivo bone resorption defects in PLCc2
) ⁄ ) mice [42,43].
Although all three reports conclude that PLCc2 is required for
in vitro osteoclast development and basal bone resorption in
vivo, they provide different explanations for those observations.
Mao et al. [42] and Chen et al. [43] reported dramatically
reduced expression of osteoclast-speciﬁc genes (such as those
encoding TRAP, NFATc1, cathepsin K or the calcitonin recep-
tor) in PLCc2
) ⁄ ) cultures, suggesting that PLCc2 is required for
an early step of osteoclast differentiation. A plausible explana-
tion was that a PLCc2-induced intracellular Ca
2+ signal trig-
gered activation of NFATc1, a Ca
2+-sensitive master regulator
of osteoclast-speciﬁc gene expression [31]. Surprisingly, our
own more detailed analyses did not reveal any substantial
defect of osteoclast-speciﬁc gene expression in PLCc2
) ⁄ )
cultures, and the expression of NFATc1 was not at all affected
by the PLCc2 mutation (Fig. 4b). Based on the time course of
the expression of those genes and their low expression in
parallel macrophage samples (Fig. 4b), it is unlikely that our
results are attributed to non-speciﬁc ampliﬁcation artefacts. It is
also unlikely that our results are owing to inappropriate
selection of the cytokine concentrations used because we did
not observe reduced gene expression levels in PLCc2
) ⁄ )
cultures even when the concentration of both M-CSF and
RANKL was reduced to 20 ng⁄mL, whereas the PLCc2
) ⁄ )
mutation caused severe osteoclast developmental defect even
when the concentration of both cytokines was increased to
100 ng⁄mL (not shown). In addition, we consistently observed
a large percentage of TRAP-positive mononuclear cells in
PLCc2
) ⁄ ) osteoclast cultures (Fig. 2c), and such cells were also
present in the PLCc2
) ⁄ ) osteoclast cultures shown by Mao et al.
[42] and Chen et al. [43]. Taken together, osteoclast-speciﬁc
gene expression is not (or not completely) blocked in PLCc2
) ⁄ )
cultures, necessitating alternative explanations for the
PLCc2
) ⁄ ) osteoclast phenotype.
Another possible explanation for the PLCc2
) ⁄ ) osteoclast
phenotype could be the participation of PLCc2 in preosteoclast
fusion, a process mediated in part by the DC-STAMP molecule
[37,38]. While our gene expression studies (Fig. 4b) did not
reveal any major role for PLCc2 in RANKL-induced upregula-
tion of DC-STAMP, it has yet to be tested whether PLCc2i s
involved in signal transduction by DC-STAMP or another
preosteoclast fusion receptor.
Osteoclast development requires a complex interplay
between signals from M-CSF, RANKL and ligation of adhesion
receptors [44]. Because RANKL stimulation of adherent
bone marrow-derived macrophages triggered PLCc2
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PLCc2 IN BONE METABOLISMphosphorylation, Mao et al. [42] and Chen et al. [43] suggested
that PLCc2 is activated downstream of RANK. That conclusion,
however, is confounded by the ligation of both RANK and
adhesion receptors in that assay. In contrast, we did not observe
any PLCc2 phosphorylation upon stimulating wild-type macro-
phages with RANKL (or M-CSF) in suspension, whereas cellu-
lar adhesion consistently triggered robust phosphorylation of
the protein in the absence of any cytokines (Fig. 5b,c). These
results suggest that PLCc2 is primarily involved in adhesion
receptor rather than in RANK signal transduction, a possibility
consistent with the role of PLCc2 in integrin signalling of neu-
trophils [24,26] and its proposed modulatory effect on integrin
signalling in preosteoclasts [45].
The analysis of ovariectomy-induced bone resorption is likely
the most clinically relevant aspect of our study. While the
increased basal bone volume (Fig. 1) and the defective in vitro
osteoclast development and function (Figs 2 and 3) in PLCc2
) ⁄ )
mice suggested a role for PLCc2 in pathological bone resorp-
tion, ovariectomy-induced bone loss in PLCc2
) ⁄ ) mice was
unexpectedly normal or even more pronounced than in
wild-type animals (Fig. 6). Because this was observed both in
the distal femur and in the proximal tibia and by two
independent approaches (micro-CT and histomorphometry),
we believe that PLCc2 is not a major general component of
oestrogen deﬁciency–induced bone resorption. However, we
cannot exclude the possibility that ovariectomy-induced bone
resorption at certain sites or under some speciﬁc conditions
would be defective in PLCc2
) ⁄ ) animals.
It is at present unclear to us how exactly PLCc2
) ⁄ ) animals
are able to reduce their bone mass during oestrogen deﬁciency.
However, the fact that the ovariectomy-induced increase in the
number of osteoclasts was similar in the two genotypes despite
signiﬁcantly reduced basal number of osteoclasts in PLCc2
) ⁄ )
mice (Fig. 6e) suggests the existence of PLCc2-independent
mechanisms triggering oestrogen deﬁciency–induced osteoclast
development. Whether those are mediated by cell–cell interac-
tions (e.g. with osteoblasts) not present in the in vitro cultures
[10,11], by excessive release of cytokines overcoming osteoclast
developmental defects [46] or by the ampliﬁcation of PLCc2-
independent signal transduction pathways, should be the
subject of future research.
It has been generally believed that osteoclasts use similar
signal transduction pathways during basal and induced (e.g.
oestrogen deﬁciency–induced) bone resorption. Therefore, it
has been assumed that the identiﬁcation of novel osteoclast
signalling molecules may provide suitable targets for the
therapeutic intervention in pathological bone loss, such as
postmenopausal osteoporosis. Our results showing normal
ovariectomy-induced bone loss in PLCc2
) ⁄ ) animals indicate
that this may not be the case. Interestingly, a prior study
showed that ovariectomy-induced bone loss in the highly
osteopetrotic DAP12
) ⁄ )FcRc
) ⁄ ) animals is comparable to, or
even higher than, that in wild-type mice [47]. All these results
suggest differential osteoclast signalling requirements for basal
and oestrogen deﬁciency–induced bone resorption and indi-
cate that care should be taken when extrapolating ﬁndings on
basal bone resorption to pathological conditions. These results
also indicate that limited clinical beneﬁt can be expected
from therapeutic targeting of PLCc2 in postmenopausal
osteoporosis.
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